Adaptimmune Therapeutics plc (NASDAQ:ADAP) Sees Significant Increase in Short Interest

Adaptimmune Therapeutics plc (NASDAQ:ADAPGet Free Report) was the target of a significant growth in short interest in December. As of December 31st, there was short interest totalling 5,500,000 shares, a growth of 8.7% from the December 15th total of 5,060,000 shares. Based on an average daily trading volume, of 2,120,000 shares, the days-to-cover ratio is currently 2.6 days.

Adaptimmune Therapeutics Stock Down 1.7 %

ADAP stock opened at $0.58 on Tuesday. The company’s 50 day moving average price is $0.63 and its 200 day moving average price is $0.90. The firm has a market capitalization of $148.39 million, a price-to-earnings ratio of -2.64 and a beta of 2.24. Adaptimmune Therapeutics has a fifty-two week low of $0.53 and a fifty-two week high of $2.05. The company has a debt-to-equity ratio of 0.62, a quick ratio of 3.82 and a current ratio of 3.85.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the company. HC Wainwright decreased their target price on Adaptimmune Therapeutics from $4.00 to $3.50 and set a “buy” rating on the stock in a research note on Thursday, November 14th. Mizuho reduced their price target on shares of Adaptimmune Therapeutics from $3.00 to $1.50 and set an “outperform” rating on the stock in a research report on Wednesday, November 27th. Guggenheim dropped their price objective on shares of Adaptimmune Therapeutics from $4.00 to $3.00 and set a “buy” rating for the company in a report on Friday, November 15th. Finally, StockNews.com lowered shares of Adaptimmune Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Thursday, November 14th. Five research analysts have rated the stock with a buy rating, According to MarketBeat, the stock has an average rating of “Buy” and an average price target of $2.79.

Read Our Latest Analysis on ADAP

Institutional Investors Weigh In On Adaptimmune Therapeutics

Several institutional investors have recently modified their holdings of the company. Virtu Financial LLC raised its holdings in Adaptimmune Therapeutics by 27.5% during the third quarter. Virtu Financial LLC now owns 101,008 shares of the biotechnology company’s stock worth $96,000 after purchasing an additional 21,769 shares in the last quarter. Vontobel Holding Ltd. grew its position in shares of Adaptimmune Therapeutics by 230.8% in the 3rd quarter. Vontobel Holding Ltd. now owns 43,000 shares of the biotechnology company’s stock valued at $41,000 after buying an additional 30,000 shares during the last quarter. Fullcircle Wealth LLC purchased a new stake in Adaptimmune Therapeutics in the third quarter valued at $33,000. FMR LLC boosted its stake in Adaptimmune Therapeutics by 3.0% in the third quarter. FMR LLC now owns 1,740,900 shares of the biotechnology company’s stock valued at $1,655,000 after acquiring an additional 50,419 shares in the last quarter. Finally, Jane Street Group LLC boosted its stake in Adaptimmune Therapeutics by 130.4% in the third quarter. Jane Street Group LLC now owns 174,157 shares of the biotechnology company’s stock valued at $166,000 after acquiring an additional 98,581 shares in the last quarter. 31.37% of the stock is owned by hedge funds and other institutional investors.

About Adaptimmune Therapeutics

(Get Free Report)

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.

Read More

Receive News & Ratings for Adaptimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.